01032nas a2200361   4500000000100000000000100001000000100002008004100003653000900044653001100053653001100064653000900075653004100084653003200125653004200157653006800199653003500267100001500302700001400317700001900331700001500350700001400365700001300379700001200392700001800404700001600422700001300438245017300451250001500624300001000639490000700649020001400656       2024                            d10aMale10aHumans10aFemale10aAged10a*Osteoporotic Fractures/epidemiology10aCost-Effectiveness Analysis10a*Cardiovascular Diseases/drug therapy10a*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use10aDiphosphonates/therapeutic use1 aB. Guthrie1 aG. Rogers1 aS. Livingstone1 aD. Morales1 aP. Donnan1 aS. Davis1 aJ. Youn1 aR. Hainsworth1 aA. Thompson1 aK. Payne00aThe implications of competing risks and direct treatment disutility in cardiovascular disease and osteoporotic fracture: risk prediction and cost effectiveness analysis  a2024/02/29  a1-2750 v12  a2755-0060